Ensysce Biosciences CMO Dr. Nily Osman resigns; Dr. William Schmidt appointed interim CMO

Ensysce Biosciences, Inc.

Dr. Nily Osman resigned as Chief Medical Officer effective September 15, 2022.
Dr. William K. Schmidt appointed interim Chief Medical Officer effective same date; he previously served as CMO from Jan 2016 to Apr 2022.
Dr. Schmidt has over 25 years of pharma experience and led clinical development for Entereg (alvimopan) at Adolor Corporation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Dr. William K. Schmidt

interim Chief Medical Officer

ENSC · Ensysce Biosciences, Inc.

Effective: 2022-09-15
Filed: September 16, 2022, 7:59 PM ET

The Company has appointed Dr. William K. Schmidt, Ph.D. as the Company's interim Chief Medical Officer, effective as of September 15, 2022.

Departed

Dr. Nily Osman

Chief Medical Officer

ENSC · Ensysce Biosciences, Inc.

Effective: 2022-09-15
Successor: Dr. William K. Schmidt
Filed: September 16, 2022, 7:59 PM ET

tender of resignation from its Chief Medical Officer, Dr. Nily Osman, such resignation effective as of September 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. William K. Schmidt was appointed as interim Chief Medical Officer at Ensysce Biosciences, Inc..

Action: appointed
Role: interim Chief Medical Officer

Exact text from the filing

The Company has appointed Dr. William K. Schmidt, Ph.D. as the Company's interim Chief Medical Officer, effective as of September 15, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Nily Osman resigned as Chief Medical Officer at Ensysce Biosciences, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

tender of resignation from its Chief Medical Officer, Dr. Nily Osman, such resignation effective as of September 15, 2022.

View on SEC.gov

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-026119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.